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Introduction to the session  














Each table addresses one topic
Identifies other key points
One  person per table to take notes










1. How do you define a batch for continuous & semi-continuous processes 
from a regulatory perspective?
2. Validation of continuous processes how do we meet current regulatory 
expectations?
3. How do we meet regulatory requirements requiring us to demonstrate 
viral reduction throughout the process?
4. What PAT technologies are needed to support robust in-line monitoring?
5. What are your in-process bioburden control strategies?
6. How and where are samples taken in a continuous process?
7. What are implications of system integration from a regulatory 
perspective?

1. How do you define a 
batch for continuous & 
semi-continuous 
processes from a 
regulatory perspective?
• How did you/will you define a batch for continuous 
processes? 
• What data did you use/would you use to justify the 
batch definition?
• What in-process pooling criteria did you/will you 
use for processes with variable PQ day to day?
• How much PQ variability is acceptable a particular 
release specification (e.g., glycosylation level, 
charge heterogeneity)? What data would you have 
to justify your stance?
• Are any of the above dependent on MOA (e.g., 
nuances in batch to batch consistency for a-fucose)?
• What are the implications of start up and shutdown
2. Validation of 
continuous processes 
how do we meet current 
regulatory expectations?
• Process characterization needs to account for the 
connectivity between steps. What is your approach 
for DOE – partition design vs testing isolated unit 
operations?
• How do you show the process is in a state of 
control? 
• For instance, how do you demonstrate cycle-to-
cycle consistency on downstream chromatography 
columns that are cycled 50-200 times? 
• What data would you show to justify your stance?
• Are there different strategies for Upstream 
compared to Downstream 
3. How do we meet 
regulatory requirements 
requiring us to 
demonstrate viral 
reduction throughout the 
process? 
• How do you validate continuous virus inactivation? 
• How do you validate VRF in a continuous process?
• How do you demonstrate viral clearance in a 
continuous chromatography column
• Do you use one membrane system continuously for 
14-60 days? 
• Or do you change membranes every day? 
• What are the criteria to be used for changing them?
4. What PAT technologies 
are needed to support 
robust in-line monitoring?
• How do you show the process is in a state of 
control? 
• For normal steady state, start-up and shutdown 
considerations
• For instance, how do you demonstrate cycle-to-
cycle consistency on downstream chromatography 
columns that are cycled 50-200 times? 
• What data would you show to justify your stance?
• Can we use PAT to adjust process perturbations in 
real time steering process to a optimum?
• How do you manage process deviations? 
5. What are your in-
process bioburden 
control strategies? 
• What are your in-process bioburden control strategies 
for processes that operate continuously for 14 – 60 days 
downstream? 
• Do you sanitize everything daily?
• Do you rely on sterile materials and filters and forgo 
sanitization? 
• How do you change non active SU components (bags 
tubing)
6. How and where are 
samples taken in a 
continuous process? 
• Methods for taking a sample
• Frequency
• Device and controller delays
• Uniformity
• Start up vs. steady state
7. What are implications of 
system integration from a 
regulatory perspective?
• Do we need increased understanding of the interaction 
between linked unit operations?
• To ensure stable operation
• Resident time distributions
• Implication for feedback/feedforward control
• Are there data management issues
• How do we deal with changes and disturbances?
• Raw materials
• Changes in process conditions (titre from the bioreactor)
Wrap Up 5 min/group
• What did you discuss
• Conclusions
• Unresolved issues
• Other points for consideration
Thank you
